The term "the common cold" does not denote a precisely defined disease, yet the characteristics of this illness are familiar to most people. The common cold is the leading cause of acute morbidity and of visits to a physician in Western countries, and a major cause of absenteeism from work and school. The common cold is usually caused by respiratory viruses, and therefore antibiotics are useless for a typical acute common cold episode. Other potential treatment options are of substantial public health interest.
Since the isolation of vitamin C in the 1930s, it has been repeatedly suggested that it might affect respiratory infections. The possible role of vitamin C on the common cold became particularly popular in the 1970s, when Nobel Prize winner Linus Pauling concluded from the earlier placebo-controlled trials that large dose vitamin C supplementation would substantially reduce the incidence of colds. Pauling's activity led the initiation of new trials focusing on the role of vitamin C on colds.
This review was restricted to placebo-controlled trials in which at least 200 mg per day of vitamin C was administered to the study group.
The trials analyzed here show that regular ingestion of vitamin C has no effect on common cold incidence in the ordinary population. Nevertheless, six trials with participants exposed to short periods of extreme physical and/or cold stress (including marathon runners and skiers) showed reduction in common cold risk by half.
Regular vitamin C supplementation was fairly consistently associated with a small reduction in the duration and severity of common cold symptoms pointing to a definite physiological effect in respiratory defense mechanisms. However, the magnitude of the effect was small and raises doubt about its clinical usefulness.
When high doses of vitamin C have been administered therapeutically, starting after the onset of cold symptoms, there has been no consistent effect on either the duration or severity of symptoms. However, few such therapeutic trials have been carried out and their quality has been variable. One large trial reported equivocal benefit from an 8 gram therapeutic dose at onset of symptoms, and two trials using five-day supplementation reported benefit, pointing to the need for further therapeutic trials to examine the effects of large vitamin C doses. Finally, none of the therapeutic trials carried out so far examined children, even though the regular supplementation trials reported substantially greater effect on duration in children.